← Back to Treatments
🏅 FDA Orphan Designation

Enspryng

SATRALIZUMAB

Manufacturer: Genentech, Inc.

Indicated for:
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodiesOrphanNeuromyelitis optica spectrum disorder

FDA-Approved Indications (2)

treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Population: adults who are anti-aquaporin-4 (AQP4) antibody positive

Indications & Usage

1 INDICATIONS AND USAGE ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )

💙 Support Programs

View all →
Enspryng
Genentech, Inc.
Apply ↗
Enspryng
Genentech
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.